Alphatec Holdings (ATEC) Earnings Date & Reports
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma... Show more
ATEC is expected to report earnings to rise 18.83% to 7 cents per share on July 30
Alphatec Holdings (ATEC) Q1 2026 Earnings Recap: Revenue Grows but Misses Estimates
Key Takeaways
- Alphatec Holdings reported Q1 2026 total revenue of $192 million, up 14% year-over-year but below consensus estimates of approximately $197 million.
- Surgical revenue rose 17% to $178 million, driven by 21% growth in case volume and 23% increase in net new surgeon users.
- EOS revenue fell 18% to $14 million, contributing to the overall revenue shortfall.
- GAAP net loss narrowed to $34 million ($0.22 per share) from $52 million ($0.35 per share) in Q1 2025.
- Adjusted EBITDA improved to $21 million (11% margin), up 460 basis points year-over-year.
- Full-year 2026 guidance adjusted to $882 million in total revenue, with surgical revenue at $805 million and adjusted EBITDA at $134 million.
Earnings Context and Why It Matters
Alphatec Holdings (ATEC), a spine-focused medical technology company, released its first quarter 2026 earnings on May 5, 2026, for the period ended March 31, 2026. This report is critical for investors as it highlights the company's progress in expanding its surgical ecosystem amid competitive pressures in the spinal implant market. Recent quarters showed robust growth, with full-year 2025 revenue up 25% to $764 million. However, challenges in the EOS imaging segment tested execution. Investors watch these results closely for signals on surgeon adoption, procedural volumes, and margin expansion, which could influence ATEC's path to profitability in a sector where innovation drives market share.
Alphatec reported total revenue of $192 million for Q1 2026, a 14% increase from $169 million in Q1 2025, but short of consensus expectations around $197 million. Surgical revenue, the core segment, grew 17% to $178 million, fueled by 21% higher case volumes and broader product adoption. EOS revenue declined 18% to $14 million due to fewer system deliveries.
GAAP gross margin expanded to 71% from prior year, with non-GAAP at 72%. GAAP operating expenses were $159 million, leading to an operating loss of $23 million, improved from $44 million last year. Adjusted EBITDA reached $21 million, or 11% of revenue. GAAP net loss was $34 million, or $0.22 per share, better than the $0.35 loss per share in Q1 2025 and beating some non-GAAP EPS views at break-even. Cash stood at $140 million, supported by a new debt refinancing saving over $6 million annually in interest.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your analysis.
Market Reaction and Investor Sentiment
ATEC shares plunged over 30% on May 6, 2026, closing at $6.99 after a prior close of $10.23, reflecting disappointment over the revenue miss despite surgical strength and loss narrowing. Sentiment focused on EOS weakness and lowered full-year guidance, overshadowing positives like EBITDA growth and debt cost savings. Traders noted volume surges and post-earnings volatility.
Forward Outlook and Key Factors to Monitor
Alphatec adjusted its full-year 2026 guidance to $882 million in total revenue, implying 15% growth, with surgical revenue steady at $805 million (17% growth) and EOS at $77 million. Adjusted EBITDA remains $134 million (15% margin), signaling confidence in operating leverage. Free cash flow is expected at least $20 million.
Investors should track surgeon adoption and case volumes, as 23% net new surgeon growth and innovations like Valence navigation and patient-specific rods drive momentum. EOS recovery via EOS Insight software, which boosts post-adoption revenue by 30%, is key after Q1 softness.
Margin trends benefit from product mix and efficiency, while the new $300 million bank facility (to 2031) cuts interest by $6 million yearly. Upcoming catalysts include Japan expansion and Q2 procedural data. Industry dynamics like reimbursement and competition remain watchpoints, alongside execution on guidance amid economic pressures.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a holding company with interests in medical equipment and supplies
Industry MedicalNursingServices